Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nischarin is a cytosolic scaffolding protein that acts as a negative regulator of cell migration and cytoskeletal organization. It binds to integrin α5β1, inhibits Rac-mediated activation pathways, and modulates FAK phosphorylation, PAK/LIMK signaling, and Rac GTP loading. It is considered a functional candidate for the imidazoline-1 receptor (I1R) and exhibits tumor-suppressor-like characteristics. It interacts with integrins, IRS4, and Rac/Rab GTPases, influencing trafficking and signal modulation relevant to cancer biology and cellular motility control.
Agonist for imidazoline-1 receptor (I1R) signaling (for Tizanidine, Agmatine, Moxonidine); inhibition of Nischarin (Tepotinib - mechanism unclear, direct action on Nischarin not established)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nischarin.